Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors

BACKGROUND: Avapritinib, a novel inhibitor of KIT/PDGFRA, is approved in the U.S. for the treatment of adults with PDGFRA exon 18‐mutant unresectable or metastatic gastrointestinal stromal tumors (U/M GISTs). We assessed the safety of avapritinib and provide evidence‐based guidance on management of...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Joseph, Cissimol P., Abaricia, Sarah N., Angelis, Michelle A., Polson, Kathleen, Jones, Robin L., Kang, Yoon‐Koo, Riedel, Richard F., Schöffski, Patrick, Serrano, César, Trent, Jonathan, Tetzlaff, Eric D., Si, Tuan Dong, Zhou, Teresa, Doyle, Ashley, Bauer, Sebastian, Roche, Maria, Havnaer, Tracy
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Inc. 2021
Konular:
Gastrointestinal Cancer
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018323/
https://ncbi.nlm.nih.gov/pubmed/33301227
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13632
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller